151 related articles for article (PubMed ID: 16413350)
1. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy.
Faria SL; Mahmud S; Souhami L; David M; Duclos M; Shenouda G; Makis W; Freeman CR
Urology; 2006 Jan; 67(1):142-6. PubMed ID: 16413350
[TBL] [Abstract][Full Text] [Related]
2. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
[TBL] [Abstract][Full Text] [Related]
4. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
[TBL] [Abstract][Full Text] [Related]
5. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
6. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
7. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
8. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.
Zelefsky MJ; Ben-Porat L; Chan HM; Fearn PA; Venkatraman ES
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):382-8. PubMed ID: 16965990
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
Stock RG; Klein TJ; Cesaretti JA; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.
Horwitz EM; Levy LB; Thames HD; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Cancer; 2006 Oct; 107(7):1496-502. PubMed ID: 16944536
[TBL] [Abstract][Full Text] [Related]
12. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516
[TBL] [Abstract][Full Text] [Related]
13. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
15. In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval.
Soto DE; Andridge RR; Pan CC; Williams SG; Taylor JM; Sandler HM
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1295-301. PubMed ID: 18472361
[TBL] [Abstract][Full Text] [Related]
16. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
17. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
18. Biochemical failure as single abnormality in patients with prostate cancer following radical treatment with external radiotherapy: follow-up without immediate treatment.
Faria SL; Salah M; David M; Souhami L; Duclos M; Shenouda G; Deblois F; Janick C; Freeman CR
Int Braz J Urol; 2004; 30(4):289-95; discussion 295. PubMed ID: 15679959
[TBL] [Abstract][Full Text] [Related]
19. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
20. The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment.
Ciezki JP; Reddy CA; Stephenson AJ; Angermeier K; Ulchaker J; Altman A; Chehade N; Klein EA
Urology; 2010 Feb; 75(2):467-71. PubMed ID: 19864003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
